Journal
BIOMATERIALS
Volume 196, Issue -, Pages 67-79Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2017.11.023
Keywords
Mesenchymal stem cells; Bone regeneration; Microtissue; MSC amplification
Funding
- National Key Research and Development Program of China [2017YFA0104902, 2016YFB0700804]
- National High Technology Research and Development Program of China (863 Program) [2015AA020303]
- NSFC [81630065, GZ1094, 81472115, 81672162, 81772354, 81572137, 81371964]
- Key scientific and technological innovation team of Zhejiang Province [2013TD11]
Ask authors/readers for more resources
Mesenchymal stem cells (MSCs) have gained increasing attention as a potential approach for the treatment of bone injuries due to their multi-lineage differentiation potential and also their ability to recognize and home to damaged tissue sites, secreting bioactive factors that can modulate the immune system and enhance tissue repair. However, a wide gap between the number of MSCs obtainable from the donor site and the number required for implantation, as well as the lack of understanding of MSC functions under different in vitro and in vivo microenvironment, hinders the progression of MSCs toward clinical settings. The clinical translation of MSC5 pre-requisites a scalable expansion process for the biomanufacturing of therapeutically qualified cells. This review briefly introduces the features of implanted MSCs to determine the best strategies to optimize their regenerative capacity, as well as the current MSC implantation for bone diseases. Current achievements for expansion of MSC5 using various culturing methods, bioreactor technologies, biomaterial platforms, as well as microtissue-based expansion strategies are also discussed, providing new insights into future large-scale MSC expansion and clinical applications. (C) 2017 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available